The study from the American Medical Association is based on data from commercial and Medicare Part D plans. The analysis found market share for PBMs is heavily concentrated, leading to higher drug costs.
The American Telemedicine Association, an industry lobby representing companies and providers, fears a crackdown from the DEA would harm patients who rely on virtual care to get vital treatments.